Reuters on MSN2h
J&J's oral skin disease drug meets main goals of late-stage study
The once-daily pill, icotrokinra, was tested in patients with moderate-to-severe plaque psoriasis, a skin condition that ...
Business Insider14h
Protagonist and JNJ say icotrokinra study for PsO meets endpoint
In the ICONIC-LEAD study, once-daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis. At week 16, nearly two-thirds of ...
J&J's skin disease drug meets main goals of late-stage study
Johnson & Johnson's drug for a type of skin condition met the main goals in a late-stage trial, the drugmaker said on Monday.